Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer(University Hospital of Zurich), Dirk Schadendorf(National Center for Tumor Diseases), Mario Mandalà(University of Perugia), Jan C. Brase(Novartis (Switzerland)), Pier Francesco Ferrucci(MultiMedica), Keith T. Flaherty(Cancer Research Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), T Haas(Novartis (United States)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Aisha Masood(Novartis (United States)), Jean‐Jacques Grob(Aix-Marseille Université), Eduard Gasal, Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), Paul Lorigan(Manchester Academic Health Science Centre), Georgina V. Long(The University of Sydney), Daniil Stroyakovskiy(Shikoku Cancer Center), О. В. Леонов(Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center"), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Steve Green(Plant & Food Research), Antoni Ribas(University of California, Los Angeles), Paul Nathan(Mount Vernon Hospital), Helen Gogas(National and Kapodistrian University of Athens), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Caroline Robert(Institut Gustave Roussy), Ana Arance(Hospital Clínic de Barcelona)
Cited by 146
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k